

- **Name:** Young Kwang Chae
 - **Current Position & Affiliation:** Associate Professor of Medicine Co-Director, Early Phase Clinical Trials Unit, Robert H. Lurie Comprehensive Cancer Center of Northwestern University Co-Director, Developmental Therapeutics Fellowship Program, Division of Hematology Oncology, Department of Medicine, Feinberg School of Medicine, Northwestern University Jul, 2014-Present
 - **Country:** USA
-

• **Educational Background:**

MD, Seoul National University, South Korea, 2002

MPH, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, Public Health, Epidemiology and Biostatistics, 2007

MBA, Johns Hopkins University Carey Business School, Baltimore, Maryland, Business Administration, Medical Management, 2007

Residency, Internal Medicine, Albert Einstein Medical Center, Philadelphia, Pennsylvania, Jul 2008-Jun 2011

Fellowship, Hematology and Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, Jul 2011- Jun 2014

CREDENTIALS Board Certification Internal Medicine, American Board of Internal Medicine, 2011 Medical Oncology, American Board of Internal Medicine, 2014

• **Professional Experience:**

Member, Lung Committee & Lung Working Group, Southwest Oncology Group (SWOG) 2015 – present

Vice Chair, Early Therapeutics and Rare Cancer Committee, Southwest Oncology Group (SWOG) 2015 - present

Member, Molecular Tumor Board, ASCO Targeted Agent and Profiling Utilization Registry (TAPUR) Study

Chair, Developmental Therapeutics Program Clinical Research Meeting, Robert H. Lurie Comprehensive Cancer Center

Co-Leader, Early Therapeutics Multi-histology Disease Team, Robert H. Lurie Comprehensive Cancer Center

• **Professional Organizations:**

Member, Lung Committee & Lung Working Group, Southwest Oncology Group (SWOG) 2015 – present

Vice Chair, Early Therapeutics and Rare Cancer Committee, Southwest Oncology Group (SWOG) 2015 - present
Member, Molecular Tumor Board, ASCO Targeted Agent and Profiling Utilization Registry (TAPUR) Study

• **Main Scientific Publications:**

1. Chae YK, Hong F, Vaklavas C, Cheng HH, Hammerman P, Mitchell EP, Zwiebel JA, Ivy SP, Gray RJ, Li S, McShane LM, Rubinstein LV, Patton D, Williams PM, Hamilton SR, Mansfield A, Conley BA, Arteaga CL, Harris LN, O'Dwyer PJ, Chen AP, Flaherty KT. Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W. *J Clin Oncol*. 2020 Jul 20;38(21):2407-2417. doi: 10.1200/JCO.19.02630. Epub 2020 May 28.
2. Patel SP, Mayerson E, Chae YK, Strosberg J, Wang J, Konda B, Hayward J, McLeod CM, Chen HX, Sharon E, Othus M, Ryan CW, Plets M, Blanke CD, Kurzrock R. A phase II basket trial of Dual Anti-CTLA-4 and Anti PD-1 Blockade in Rare Tumors (DART) SWOG S1609: High-Grade Neuroendocrine Neoplasm Cohort. *Cancer*. 2021 Apr 21. doi: 10.1002/cncr.33591.
3. Wagner MJ, Othus M, Patel SP, Ryan C, Sangal A, Powers B, Budd GT, Victor AI, Hsueh CT, Chugh R, Nair S, Leu KM, Agulnik M, Sharon E, Mayerson E, Plets M, Blanke C, Streicher H, Chae YK, Kurzrock R. Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART). *J Immunother Cancer*. 2021 Aug;9(8):e002990. doi: 10.1136/jitc-2021-002990. PMID: 34380663.
4. Adams S, Othus M, Patel SP, Miller KD, Chugh R, Schuetze SM, Chamberlin MD, Haley BJ, Storniolo AMV, Reddy MP, Anderson SA, Zimmerman CT, O'Dea AP, Mirshahidi HR, Ahnert JR, Brescia FJ, Hahn O, Raymond JM, Biggs DD, Connolly RM, Sharon E, Korde LA, Gray RJ, Mayerson E, Plets M, Blanke CD, Chae YK, Kurzrock R. A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti-CTLA-4 and Anti-PD 1 Blockade in Rare Tumors (DART, SWOG S1609). *Clin Cancer Res*. 2022 Jan 15;28(2):271-278. doi: 10.1158/1078-0432.CCR-21-2182. Epub 2021 Oct 29. PMID: 34716198.
5. Kim ES, Velcheti V, Mekhail T, Yun C, Shagan SM, Hu S, Chae YK, Leal TA, Dowell JE, Tsai ML, Dakhil CSR, Stella P, Jin Y, Shames DS, Schleifman E, Fabrizio DA, Phan S, Socinski MA. Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial. *Nat Med*. 2022 May;28(5):939-945. doi: 10.1038/s41591-022-01754-x. Epub 2022 Apr 14. PMID: 35422531; PMCID: PMC9117143.